De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

BiomX Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Jonathan Solomon

Algemeen directeur

US$1.1m

Totale compensatie

Percentage CEO-salaris	36.8%
Dienstverband CEO	5yrs
Eigendom CEO	0.3%
Management gemiddelde ambtstermijn	5yrs
Gemiddelde ambtstermijn bestuur	less than a year

Recente managementupdates

Recent updates

What Kind Of Shareholders Own BiomX Inc. (NYSEMKT:PHGE)?

Jan 29

Analyse CEO-vergoeding

Hoe is Jonathan Solomon's beloning veranderd ten opzichte van BiomX's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$26m
Mar 31 2024	n/a	n/a	-US$34m
Dec 31 2023	US$1m	US$412k	-US$26m
Sep 30 2023	n/a	n/a	-US$27m
Jun 30 2023	n/a	n/a	-US$25m
Mar 31 2023	n/a	n/a	-US$27m
Dec 31 2022	US$1m	US$425k	-US$28m
Sep 30 2022	n/a	n/a	-US$33m
Jun 30 2022	n/a	n/a	-US$36m
Mar 31 2022	n/a	n/a	-US$36m
Dec 31 2021	US$1m	US$391k	-US$36m
Sep 30 2021	n/a	n/a	-US$35m
Jun 30 2021	n/a	n/a	-US$34m
Mar 31 2021	n/a	n/a	-US$33m
Dec 31 2020	US$1m	US$339k	-US$30m
Sep 30 2020	n/a	n/a	-US$27m
Jun 30 2020	n/a	n/a	-US$23m
Mar 31 2020	n/a	n/a	-US$22m
Dec 31 2019	US$937k	US$286k	-US$21m
Sep 30 2019	n/a	n/a	-US$22m
Jun 30 2019	n/a	n/a	-US$19m
Mar 31 2019	n/a	n/a	-US$17m
Dec 31 2018	US$605k	US$276k	-US$15m
Dec 31 2017	US$566k	US$266k	-US$7m

Compensatie versus markt: De totale vergoeding ($USD 1.12M ) Jonathan } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 677.23K ).

Compensatie versus inkomsten: De vergoeding van Jonathan is gestegen terwijl het bedrijf verliesgevend is.

CEO

Jonathan Solomon (47 yo)

5yrs

Tenure

US$1,118,541

Compensatie

Mr. Jonathan Eitan Solomon, MBA, serves as Chief Executive Officer and Director of BiomX Inc. since October 2019. He served as Chief Executive Officer of BiomX Ltd since February 2017 until October 2019 a...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Jonathan Solomon	CEO & Director	5yrs	US$1.12m	0.30% $ 49.5k
Marina Wolfson	CFO & Secretary	4.8yrs	US$428.26k	0.0021% $ 350.4
Merav Bassan	Chief Development Officer	5yrs	US$590.93k	0.18% $ 29.6k
Rotem Sorek	Scientific Founder	no data	geen gegevens	geen gegevens
Eran Elinav	Scientific Founder	no data	geen gegevens	geen gegevens
Timothy Lu	Scientific Founder	no data	geen gegevens	geen gegevens
Inbal Benjamini-Elran	C.H.R.O	4.8yrs	geen gegevens	geen gegevens
Assaf Oron	Chief Business Officer	5yrs	US$496.21k	0.14% $ 24.1k

5.0yrs

Gemiddelde duur

47yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van PHGE is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Jonathan Solomon	CEO & Director	5yrs	US$1.12m	0.30% $ 49.5k
Jonathan Leff	Independent Director	less than a year	geen gegevens	geen gegevens
Gregory Merril	Independent Director	less than a year	geen gegevens	geen gegevens
Russell Greig	Independent Chairman of the Board	5yrs	US$161.58k	0.0021% $ 350.4
Alan Moses	Independent Director	4yrs	US$81.43k	0.0028% $ 465.5
Edward Williams	Independent Director	less than a year	US$8.79k	geen gegevens
Jesse Goodman	Independent Director	less than a year	geen gegevens	geen gegevens
Susan Blum	Independent Director	less than a year	geen gegevens	geen gegevens

0.8yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van PHGE wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.8 jaar), wat duidt op een nieuw bestuur.

BiomX Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

High number of new directors

BiomX Inc., Annual General Meeting, Jul 09, 2024

Biomx Inc. Appoints Susan Blum to Its Board of Directors and Member and Chair of the Audit Committee of the Board

BiomX Inc. Announces the Appointment of Edward L. Williams to its Board of Directors

Biomx Inc. Appoints Jason M. Marks and Michael E. Dambach to the Board of Directors

BiomX Inc. Announces Board Resignations

Recent updates

BiomX Inc. to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis Conference

Biomx Inc. to Present Positive Phase 1B/2A Clinical Trial Data for Bx004 At the European Respiratory Society (Ers) Congress 2024

New major risk - Financial position

High number of new directors

BiomX Announces NYSE American Acceptance of Plan to Regain Listing Compliance

BiomX Inc., Annual General Meeting, Jul 09, 2024

BiomX Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

BiomX Inc. to Report Q1, 2024 Results on May 21, 2024

Biomx Inc. Appoints Susan Blum to Its Board of Directors and Member and Chair of the Audit Committee of the Board

BiomX Inc. announced delayed annual 10-K filing

BiomX Inc. announced that it has received $50.013969 million in funding from Deerfield Management Company, LLC, AMR Action Fund GP, LLC, Cystic Fibrosis Foundation, Nantahala Capital Management, LLC, OrbiMed Advisors LLC

BiomX Inc. announced that it expects to receive $50.013969 million in funding

BiomX Inc. has completed a Follow-on Equity Offering in the amount of $50 million.

Biomx Announces Positive Topline Results from Part 2 of the Phase 1B/2A Trial Evaluating Bx004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis

Biomx to Present Data from Ongoing Phase 1B/2A Study Evaluating Bx004 for the Treatment of Chronic Pseudomonas Aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis

BiomX Inc. Announces the Appointment of Edward L. Williams to its Board of Directors

BiomX Inc. Announces Completion of Patient Dosing in Part 2 of Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis

Biomx Inc. to Present Part 1 Data from Phase 1B/2A Study Evaluating Bx004 for the Treatment of Chronic Pseudomonas Aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis During Late-Breaking Science Session At The46th European Cystic Fibrosis Conference

Biomx Inc. Appoints Jason M. Marks and Michael E. Dambach to the Board of Directors

BiomX Inc. Announces Board Resignations

BiomX Inc. Announces Publication in Cell of Research Demonstrating Proof-of-Concept Assessment of Orally Administered Phage Treatment in Preclinical Model of Inflammatory Bowel Disease

BiomX Announces Voluntary Delisting from the Tel Aviv Stock Exchange

BiomX Inc. Announces Dosing of the First Two Patients in Phase 1B/2A Study of Bx004 for Treatment of Chronic Respiratory Infections in Patients with Cystic Fibrosis

BiomX Inc., Annual General Meeting, Aug 24, 2022

Price target decreased to US$10.25

BiomX Inc. to Report Q1, 2022 Results on May 11, 2022

CF Foundation Awards Up to $5 Million to BiomX for Potential Phage Therapy

Price target decreased to US$19.00

High number of new directors

BiomX Inc. announced delayed 10-Q filing

BiomX Inc. Announces Dosing of First Subject in Phase 2 Study of BX001 for Acne-Prone Skin

New 90-day high: US$8.40

New 90-day high: US$7.11

BiomX Announces Positive Results of a Phase 1a Pharmacokinetic Study for Inflammatory Bowel Disease/Primary Sclerosing Cholangitis (IBD/PSC) Evaluating Delivery of Oral BX002 Phage Therapy

What Kind Of Shareholders Own BiomX Inc. (NYSEMKT:PHGE)?

New 90-day high: US$6.97

BiomX Inc. Announces Preclinical Results of Analysis of Patient Samples and Engineering of Phage for Therapeutic Applications in Colorectal Cancer

New 90-day high: US$6.67

BiomX Inc. Presents Preclinical Results of Phage Targeting Klebsiella Pneumoniae for Primary Sclerosing Cholangitis and Inflammatory Bowel Disease

BiomX Inc. to Report Q3, 2020 Results on Nov 12, 2020

BiomX Reports Appointment of Paul Sekhri and Alan Moses to Its Board of Directors

Biomx Inc. Announces Changes to Its Board

New 90-day high - US$8.00

BiomX Inc. to Report Q2, 2020 Results on Aug 13, 2020

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd